Development of adenoviral vector-based mucosal vaccine against influenza

J Mol Med (Berl). 2011 Apr;89(4):331-41. doi: 10.1007/s00109-010-0696-0. Epub 2010 Nov 21.


The recent pandemic threat of the influenza virus makes the increased safety and efficiency of vaccination against the pathogen a most important issue. It has been well established that for maximum protective effect, the vaccination should mimic natural infection. Therefore, recent efforts to develop a new influenza vaccine have focused on intranasal immunization strategies. Intranasal immunization is capable of inducing secretory IgA and serum IgG responses to provide a double defense against mucosal pathogens. On the other hand, it is desirable that a live pathogen is not present in the vaccine. In addition, for optimal induction of the immune responses via the nasal route, efficient and safe mucosal adjuvants are also required. This is possible to attain using an adenoviral vector for vaccine development. Adenoviral vectors are capable of delivering and protecting the antigen encoding sequence. They also possess a natural mechanism for penetrating into the nasal mucous membrane and are capable of activating the innate immune response. This review describes the basic prerequisites for the involvement of recombinant adenoviruses for mucosal (nasal) vaccine development against the influenza virus.

Publication types

  • Review

MeSH terms

  • Adenoviridae* / genetics
  • Adenoviridae* / immunology
  • Animals
  • Genetic Vectors* / genetics
  • Genetic Vectors* / immunology
  • Humans
  • Influenza Vaccines / immunology*
  • Influenza, Human / immunology*
  • Influenza, Human / prevention & control
  • Mucous Membrane / immunology*
  • Respiratory System / immunology
  • Vaccines, Synthetic / immunology


  • Influenza Vaccines
  • Vaccines, Synthetic